Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model.
Johnstone
Michael T
MT
Department of Medicine, Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Ave, RW-453, Boston, MA 02115, USA. mjohnst1@bidmc.harvard.edu.
Perez
Alexandra S
AS
Nasser
Imad
I
Stewart
Robert
R
Vaidya
Anand
A
Al Ammary
Fawaz
F
Schmidt
Ben
B
Horowitz
Gary
G
Dolgoff
Jennifer
J
Hamilton
James
J
Quist
William C
WC
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001011:Aorta / Q000293:injuries* / Q000473:pathology; D001018:Aortic Diseases / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D002404:Catheterization / Q000009:adverse effects*; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000633:toxicity; D004353:Drug Evaluation, Preclinical; D004730:Endothelium, Vascular / Q000293:injuries / Q000473:pathology; D008264:Macrophages / Q000187:drug effects*; D011817:Rabbits; D012422:Rupture, Spontaneous; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D002791:Cholesterol, Dietary; D013777:Tetrazoles; D002784:Cholesterol; C077793:candesartan cilexetil